Elena Garralda, M.D.

Mary Robinson

Dr. Garralda is a medical oncologist and clinical investigator who focuses her research on targeted agents, early drug development, translational research, and immunotherapies. She received her medical degree from the Universidad Autónoma de Madrid and completed her medical oncology specialization at the Hospital Universitario Madrid. Dr. Garralda also earned a Master’s degree in molecular oncology from the Centro de Estudios …

Josep Tabernero, M.D., PhD, MSc

Mary Robinson

Dr. Josep Tabernero, who founded the IOB Institute of Oncology in Barcelona, coordinates both units. NEXT Oncology – Barcelona is in the Hospital Quirónsalud Barcelona and headed by site coordinator Dr. Elena Garralda. The opening of the two units boosts continued research activity and creates a great opportunity to promote clinical research in Spain. Josep Tabernero holds MD and PhD …

Edwin Bellido, M.D.

Mary Robinson

Edwin Bellido, MD, MSc, is a Medical Oncologist and Clinical Investigator in the NEXT Oncology Early Drug Development Unit at Hospital Universitario Quirónsalud Madrid. Edwin Bellido, received his medical degree from the Public University of Cusco in Peru, in the upper third, and immediately after completed a master’s degree in research methodology in the area of health at the University of …

Jesús Fuentes Antrás , M.D.

Mary Robinson

Jesús Fuentes Antrás, MD, MSc, is a Medical Oncologist and Clinical Investigator in the NEXT Oncology Early Drug Development Unit at Hospital Universitario Quirónsalud Madrid. Dr. Fuentes Antrás received his MD with honors in 2015 from the Universidad Autónoma de Madrid. He completed his Medical Oncology training at Hospital Clínico San Carlos in Madrid, and subsequently joined the Drug Development and …

Valentina Boni, M.D.

Mary Robinson

Dr Boni received her MD with honors cum laude in 2005 from the Catholic University of Rome, Italy. In 2009, she completed her medical training in oncology at the “Agostino Gemelli” University Hospital in Rome, Italy. Her interest in clinical research led her to join as Clinical Researcher, the Pharmacogenomic lab at the Center for Applied Medical Research (CIMA), in …

Mitul Gandhi, M.D.

Mary Robinson

Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University …

M. Adham Salkeni, MD, FRCPC

Mary Robinson

Mohamad Adham Salkeni, MD, FRCPC earned his medical degree from the University of Damascus. He then completed his residency in internal medicine at St. Louis University and fellowship in hematology and oncology at the University of Cincinnati. During his medical training, he was engaged in bench and translational research investigating inflammatory modulation of the blood-brain barrier in vivo, published in …

Alex Spira, M.D., PhD, FACP

Mary Robinson

NEXT Oncology – Virginia is headed by Alex I. Spira, MD, PhD. FACP, who serves as the site’s clinical director and CEO, as well as the co-director of the Virginia Cancer Specialists Research Institute. He is the director of the thoracic and Phase I program and a clinical assistant professor at John Hopkins.Dr. Spira sought to expand the clinic’s Phase I …

Naga K. S. Cheedella, M.D.

Mary Robinson

Dr. Cheedella is board-certified in internal medicine, specializing in hematology, and medical oncology. She is now part of NEXT Dallas as a Phase 1 clinical investigator.

Shiraj Sen, MD, PhD

Digital BTYcreative

Dr. Shiraj Sen is a medical oncologist and director of NEXT Oncology Dallas. Meeting some of the first individuals with cancer treated on modern immunotherapy clinical trials and watching them feel better and live longer after being told that there were no further standard treatments for them to receive motivated him to pursue a career in drug development in order …